About abc biopply

Building an international network of Organoid Competence Centers

In the ever-evolving landscape of drug discovery and development, abc biopply is playing a pivotal role in shaping the future of the preclinical CRO market. The market is poised to surge, reflecting a global shift toward ethical and sustainable practices, a forceful trend towards outsourced services and is backed up by new rules for animal-free IND approvals.

abc biopply realized early on that the expertise required to efficiently use organoid-based disease models far exceeds the competences of an ordinary cell culture laboratory. The underestimation of the complexity of 3D cell culture often leads to poor validation, a lack of standardization, and limited predictive power of the results. abc biopply therefore offers a distinctive organoid servicing and licensing model based on its proprietary 3D CoSeedis Multi-Organoid in chip technology™, delivering validated and standardized results. The company aims to become an “animal-free Charles River” by establishing Organoid Competence Centers in different parts of the world.

Our proprietary technology creates hundreds of miniature versions of patient organs in a laboratory setting, using both healthy and diseased tissues. Thus, our innovative technology bridge the gap in predictability between the lab and patients response. 

Since our establishment in 2018, we have collaborated with numerous clients, developing customized assays and enhancing our 3D technology platform to meet the specific needs of their projects. We kindly invite you to joint our organoid cummunity.